Large pharma drug licensing from China hits high at 28% in 2024
Large pharma drug licensing from China hits high at 28% in 2024
- The total deal value of US licensing of innovator drug candidates from Chinese biopharma companies has surged 280% since 2020.
- drug licensing agreements involving Chinese biopharma licensors has surged 66%, from $16.6 billion in 2023 to $41.5 billion in 2024